Top news of the week: 14.04.2020.
Health care, Dot-com bubble, Severe acute respiratory syndrome, Musculoskeletal disorders, Biotechnology, Health
Startups
RT @LifeSciVC: Booming VC-Backed Biopharma: Strong Market Despite Pandemic.
First quarter of 2020 was the largest quarter for U.S. biopharma venture funding ever.
https://t.co/mVhLQu2T53 https://t.co/WuQNQEyvsO
OpenBooming VC-Backed Biopharma: Strong Market Despite Pandemic
Venture capital is a long investment cycle business, and never before has that been so clear as now in the face of the ongoing COVID pandemic. Even with the unprecedented public equity ...
Pfizer says coronavirus drug could enter testing by fall
Pfizer intends to start human tests of a potential coronavirus therapy as soon as August or September, three months sooner than it had thought possible.
#Biotech startups expand efforts to combat #COVID19 https://t.co/bhi85cF0Hl https://t.co/r0P3EFtC0b
OpenBiotech Startups Expand Efforts to Combat Covid-19
Warren, N.J.-based Celularity Inc. seeks to enroll 84 patients in a clinical trial of a cell therapy, CYNK-001, that could reduce the amount of virus found in patients with Covid-19, the ...
RT @labcentral: Coming soon: our 2nd webinar on Innovation and Biotech in the time of COVID-19. Join us Tuesday, April 14 at 1:30 PM for "Advice for Start-Ups Facing Uncertainty". How can entrepreneurs continue to develop opportunities? To be discussed and more! Register: https://t.co/09Hq4KsvmP https://t.co/f8eLDZM8in
OpenInnovation and Biotech in the Time of COVID-19: Advice for Startups
Join LabCentral on Tuesday, April 14th for the second of a three-part series focused on innovation and biotech in the time of COVID-19.
RT @AndrewE_Dunn: "Anybody who continues to try to thrive and hope to God that they survive in the process is not going to do enough to ensure that survival is assured," Flagship's Noubar Afeyan told me.
His advice for small biotechs to get through this crisis:
https://t.co/EwgcIao4Dq
Open'We need to be focused on surviving': A legendary biotech investor who's founded more than 40 companies shares his top advice for startups to get through the coronavirus crisis
Noubar Afeyan's most well-known venture is Moderna, a $10 billion biotech that is now testing a coronavirus vaccine.
Via @NYTimes: More #coronavirus vaccines and treatments move toward human trials https://t.co/vE2EvnQV28
OpenMore Coronavirus Vaccine Efforts Move Toward Human Trials
Just three months after the start of the coronavirus pandemic, several biotech companies have shown promising vaccine programs and are beginning trials.
Biogen employees unwittingly spread the coronavirus from Massachusetts to Indiana, Tennessee and North Carolina https://t.co/EtNGvf7Xe8
OpenHow a Premier U.S. Drug Company Became a Virus ‘Super Spreader’
Biogen employees unwittingly spread the coronavirus from Massachusetts to Indiana, Tennessee and North Carolina.
Keros upsizes IPO, raising $96M for blood and musculoskeletal trials https://t.co/5sVlgWBJlw https://t.co/jFrKDpJZUC
OpenKeros upsizes IPO, raising $96M for blood and musculoskeletal trials
Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The upsized IPO gives Keros ...